Leukemia, Acute Clinical Trial
Official title:
Early Precision Diagnosis and Relapse Prediction Technology Development in High-risk Acute Leukemia and Clinical Application
Based on the investigator's previous data on risk classification for acute leukemia,the investigators will design a set of panels to detect the gene expression and genomic variants (SNPs, mutation, insertion, deletion and fusion genes, etc), and identify the high-risk subtypes of acute leukemia, such as Ph-like acute lymphoblastic leukemia. Furthermore, the target therapy (Tyrosine Kinase Inhibitors,et.al) will be used to treat the identified patients. In addition, more sensitive minimal residual disease (MRD) detection technology will be designed and used to detect the MRD in patients to early predict the disease relapse.
patient eligibility criteria: newly diagnosed acute leukemia patients with clinical high-risk markers, reflactory and relapsed patients. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03680677 -
Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies
|
||
Completed |
NCT04194086 -
Population Pharmacokinetics and Safety of Oral Posaconazole in Children With Leukemia
|
Phase 1/Phase 2 | |
Completed |
NCT04710212 -
Screening for Colonization With Resistant Enterobacterales in Neutropenic Patients With Hematologic Malignancies
|
||
Terminated |
NCT01050764 -
Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells
|
Phase 1/Phase 2 | |
Completed |
NCT03434704 -
Peripheral Blood Stem Cell Transplantation From Family Haploidentical Donors in Patients With Myelodysplastic Syndrome and Acute Leukemia Under Primary Prophylaxis With Posaconazole
|
Phase 2 | |
Recruiting |
NCT05823571 -
Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients
|
Phase 1 | |
Completed |
NCT04236063 -
Rehabilitation Needs of the Malaysian Haematological Cancer Survivors
|
||
Completed |
NCT04745416 -
Clinical Characteristics of Patients With Leukemia and COVID-19
|
||
Not yet recruiting |
NCT03336632 -
Chidamide Plus PTCy/Cyclosporine to Prevent GVHD After Myeloablative Conditioning, Matched PBSCT
|
Phase 2 | |
Completed |
NCT05969600 -
The Relapses in Childhood Acute Lymphoplastic Leukemia Excluding L3
|
||
Recruiting |
NCT06335277 -
Total Body Irradiation Treatments for Patients Treated at European Institute of Oncology
|
||
Recruiting |
NCT03564704 -
Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL
|
Phase 2/Phase 3 | |
Recruiting |
NCT03553238 -
Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult ETP-ALL
|
Phase 2/Phase 3 | |
Recruiting |
NCT03564470 -
Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALL
|
Phase 2/Phase 3 | |
Terminated |
NCT03963024 -
Treosulfan-TMI Conditioning and Rapamycin GvHD Prophylaxis Before Allo-HSCT
|
Phase 1 | |
Completed |
NCT04051216 -
The SMART CART Study: Health Information Technology
|
N/A | |
Recruiting |
NCT04482894 -
Palliative Care Oncology in Patients With Relapsed, Refractory, and High-Risk Leukemias or MDS
|
Phase 2 | |
Recruiting |
NCT05236296 -
Emotion and Symptom-focused Engagement for Caregivers (EASE-CG) Pilot Study
|
N/A |